- Home
- AGEN vs ANTX Comparison
AGEN vs ANTX Comparison
Compare AGEN & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGEN | ANTX |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 135.4M |
| IPO Year | 1999 | 2022 |
Fundamental Metrics
Financial Performance| Metric | AGEN | ANTX |
|---|---|---|
| Price | $3.38 | $3.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $14.50 | $2.00 |
| AVG Volume (30 Days) | 486.5K | ★ 3.4M |
| Earning Date | 03-16-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $42,877,086.00 | N/A |
| Revenue This Year | $61.42 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.89 | ★ N/A |
| Revenue Growth | ★ 89.95 | N/A |
| 52 Week Low | $1.38 | $1.00 |
| 52 Week High | $7.34 | $6.91 |
Technical Indicators
Market Signals| Indicator | AGEN | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 56.34 |
| Support Level | $2.91 | $1.05 |
| Resistance Level | $4.72 | $6.91 |
| Average True Range (ATR) | 0.27 | 0.67 |
| MACD | -0.01 | -0.18 |
| Stochastic Oscillator | 38.97 | 8.98 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.